Predictive Value of CHA2DS2-VASC Score for Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Acute Coronary Syndrome

Published:December 17, 2016DOI:
      The CHA2DS2-VASC score, used for embolic risk stratification in atrial fibrillation (AF), has been reported recently to predict adverse clinical outcomes in patients with acute coronary syndrome (ACS), regardless of having AF. We investigated the correlation between the CHA2DS2-VASC score and contrast-induced nephropathy (CIN) in patients with ACS who underwent urgent percutaneous coronary intervention (PCI). A total of 1,408 patients were enrolled in the study. The CHA2DS2-VASC score was calculated for each patient. Based on the receiver operating characteristic analysis, the study population was divided into 2 groups: CHA2DS2-VASC score ≤3 group (n = 944) and CHA2DS2-VASC score ≥4 group (n = 464). Patients were then reallocated to 2 groups according to the presence or absence of CIN. CIN was defined as a rise in serum creatinine >0.5 mg/dl or >25% increase in baseline within 72 hours after PCI. Overall, 159 cases (11.3%) of CIN were diagnosed. Receiver operating characteristic curve analysis revealed good diagnostic value of CHA2DS2-VASC score in predicting CIN (area under the curve 0.769, 95% confidence interval 0.733 to 0.805; p <0.001). When patients with a CHA2DS2-VASC score of ≥4 were compared with those with a CHA2DS2-VASC score of ≤3, patients with high score had a higher frequency of CIN (23.9% vs 5.1%; p <0.001), and multivariate analysis identified the CHA2DS2-VASC score of ≥4 as an independent predictor of CIN. In conclusion, CHA2DS2-VASC score can be used as a new, simple, and reliable tool to predict CIN in patients with ACS who underwent urgent PCI.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Camm A.J.
        • Lip G.Y.
        • De Caterina R.
        • Savelieva I.
        • Atar D.
        • Hohnloser S.H.
        • Hindricks G.
        • Kirchhof P.
        • ESC Committee for Practice Guidelines (CPG)
        2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
        Eur Heart J. 2012; 33: 2719-2747
        • Orvin K.
        • Bental T.
        • Assali A.
        • Lev E.I.
        • Vaknin-Assa H.
        • Kornowski R.
        Usefulness of the CHA2DS2-VASC score to predict adverse outcomes in patients having percutaneous coronary intervention.
        Am J Cardiol. 2016; 117: 1433-1438
        • Capodanno D.
        • Rossini R.
        • Musumeci G.
        • Lettieri C.
        • Senni M.
        • Valsecchi O.
        • Angiolillo D.J.
        • Lip G.Y.
        Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy.
        Int J Cardiol. 2015; 199: 319-325
        • Huang S.S.
        • Chen Y.H.
        • Chan W.L.
        • Huang P.H.
        • Chen J.W.
        • Lin S.J.
        Usefulness of the CHADS2 score for prognostic stratification of patients with acute myocardial infarction.
        Am J Cardiol. 2014; 114: 1309-1314
        • Ipek G.
        • Onuk T.
        • Karatas M.B.
        • Gungor B.
        • Osken A.
        • Keskin M.
        • Oz A.
        • Tanik O.
        • Hayiroglu M.I.
        • Yaka H.Y.
        • Ozturk R.
        • Bolca O.
        CHA2DS2-VASc score is a predictor of no-reflow in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous intervention.
        Angiology. 2016; 67: 840-845
        • Bozbay M.
        • Uyarel H.
        • Cicek G.
        • Oz A.
        • Keskin M.
        • Murat A.
        • Yildirim E.
        • Karaca G.
        • Ergelen M.
        • Eren M.
        CHA2DS2-VASc score predicts in-hospital and long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who were undergoing primary percutaneous coronary intervention.
        Clin Appl Thromb Hemost. 2016 May 11; ([Epub ahead of print])
        • Taşolar H.
        • Çetin M.
        • Ballı M.
        • Bayramoğlu A.
        • Otlu Y.Ö.
        • Türkmen S.
        • Aktürk E.
        CHA2DS2-VASc-HS score in non-ST elevation acute coronary syndrome patients: assessment of coronary artery disease severity and complexity and comparison to other scoring systems in the prediction of in-hospital major adverse cardiovascular events.
        Anatol J Cardiol. 2016 Mar 23; ([Epub ahead of print])
        • Ünal S.
        • Açar B.
        • Yayla Ç.
        • Balci M.M.
        • Ertem A.
        • Kara M.
        • Maden O.
        • Dereağzi Ş.F.
        Importance and usage of the CHA2DS2-VASc score in predicting acute stent thrombosis.
        Coron Artery Dis. 2016; 27: 478-482
        • Chou R.H.
        • Huang P.H.
        • Hsu C.Y.
        • Leu H.B.
        • Huang S.S.
        • Huang C.C.
        • Chen J.W.
        • Lin S.J.
        CHADS2 score predicts risk of contrast-induced nephropathy in stable coronary artery disease patients undergoing percutaneous coronary interventions.
        J Formos Med Assoc. 2016; 115: 501-509
        • Thygesen K.
        • Alpert J.S.
        • White H.D.
        • Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction
        Universal definition of myocardial infarction.
        J Am Coll Cardiol. 2007; 50: 2173-2195
        • Levey A.S.
        • Bosch J.P.
        • Lewis J.B.
        • Greene T.
        • Rogers N.
        • Roth D.
        A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.
        Ann Intern Med. 1999; 130: 461-470
        • Mehran R.
        • Nikolsky E.
        Contrast-induced nephropathy: definition, epidemiology, and patients at risk.
        Kidney Int Suppl. 2006; 100: S11-S15
        • Bartholomew B.A.
        • Harjai K.J.
        • Dukkipati S.
        • Boura J.A.
        • Yerkey M.W.
        • Glazier S.
        • Grines C.L.
        • O'Neill W.W.
        Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification.
        Am J Cardiol. 2004; 93: 1515-1519
        • Senoo T.
        • Motohiro M.
        • Kamihata H.
        • Yamamoto S.
        • Isono T.
        • Manabe K.
        • Sakuma T.
        • Yoshida S.
        • Sutani Y.
        • Iwasaka T.
        Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome.
        Am J Cardiol. 2010; 105: 624-628
        • Murphy S.W.
        • Barrett B.J.
        • Parfrey P.S.
        Contrast nephropathy.
        J Am Soc Nephrol. 2000; 11: 177-182
        • Caiazza A.
        • Russo L.
        • Sabbatini M.
        • Russo D.
        Hemodynamic and tubular changes induced by contrast media.
        Biomed Res Int. 2014; 2014: 578974
        • Hardiek K.
        • Katholi R.E.
        • Ramkumar V.
        • Deitrick C.
        Proximal tubule cell response to radiographic contrast media.
        Am J Physiol Renal Physiol. 2001; 280: F61-F70
        • Heinrich M.C.
        • Kuhlmann M.K.
        • Grgic A.
        • Heckmann M.
        • Kramann B.
        • Uder M.
        Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro.
        Radiology. 2005; 235: 843-849
        • Lucreziotti S.
        • Centola M.
        • Salerno-Uriarte D.
        • Ponticelli G.
        • Battezzati P.M.
        • Castini D.
        • Sponzilli C.
        • Lombardi F.
        Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction.
        Int J Cardiol. 2014; 174: 37-42
        • Andreucci M.
        • Solomon R.
        • Tasanarong A.
        Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention.
        Biomed Res Int. 2014; 2014: 741018
        • Heyman S.N.
        • Rosenberger C.
        • Rosen S.
        • Khamaisi M.
        Why is diabetes mellitus a risk factor for contrast-induced nephropathy?.
        Biomed Res Int. 2013; 2013: 123589
        • Kurtul A.
        • Murat S.N.
        • Yarlioglues M.
        • Duran M.
        • Ocek A.H.
        • Celik I.E.
        • Kilic A.
        • Koseoglu C.
        • Oksuz F.
        • Baris V.O.
        Procalcitonin as an early predictor of contrast-induced acute kidney injury in patients with acute coronary syndromes who underwent percutaneous coronary intervention.
        Angiology. 2015; 66: 957-963
        • Huang S.S.
        • Huang P.H.
        • Leu H.B.
        • Wu T.C.
        • Lin S.J.
        • Chen J.W.
        Association of central pulse pressure with contrast-induced nephropathy and clinical outcomes in patients undergoing coronary intervention.
        J Hypertens. 2013; 31: 2187-2194
        • Dangas G.
        • Iakovou I.
        • Nikolsky E.
        • Aymong E.D.
        • Mintz G.S.
        • Kipshidze N.N.
        • Lansky A.J.
        • Moussa I.
        • Stone G.W.
        • Moses J.W.
        • Leon M.B.
        • Mehran R.
        Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.
        Am J Cardiol. 2005; 95: 13-19
        • Rosenstock J.L.
        • Gilles E.
        • Geller A.B.
        • Panagopoulos G.
        • Mathew S.
        • Malieckal D.
        • DeVita M.V.
        • Michelis M.F.
        Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease.
        Int Urol Nephrol. 2010; 42: 1049-1054
        • Poçi D.
        • Hartford M.
        • Karlsson T.
        • Herlitz J.
        • Edvardsson N.
        • Caidahl K.
        Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation.
        Chest. 2012; 141: 1431-1440
        • Uysal O.K.
        • Turkoglu C.
        • Duran M.
        • Kaya M.G.
        • Sahin D.Y.
        • Gur M.
        • Cayli M.
        Predictive value of newly defined CHA2DS2-VASc-HSF score for severity of coronary artery disease in STEMI.
        Kardiol Pol. 2016; 74: 954-960
        • Andò G.
        • Morabito G.
        • de Gregorio C.
        • Trio O.
        • Saporito F.
        • Oreto G.
        The ACEF score as predictor of acute kidney injury in patients undergoing primary percutaneous coronary intervention.
        Int J Cardiol. 2013; 168: 4386-4387
        • Mehran R.
        • Aymong E.D.
        • Nikolsky E.
        • Lasic Z.
        • Iakovou I.
        • Fahy M.
        • Mintz G.S.
        • Lansky A.J.
        • Moses J.W.
        • Stone G.W.
        • Leon M.B.
        • Dangas G.
        A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.
        J Am Coll Cardiol. 2004; 44: 1393-1399
        • Chong E.
        • Poh K.K.
        • Lu Q.
        • Zhang J.J.
        • Tan N.
        • Hou X.M.
        • Ong H.Y.
        • Azan A.
        • Chen S.L.
        • Chen J.Y.
        • Ali R.M.
        • Fang W.Y.
        • Lau T.W.
        • Tan H.C.
        Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): a multi-centre, randomised, controlled trial.
        Int J Cardiol. 2015; 201: 237-242
        • Andò G.
        • de Gregorio C.
        • Morabito G.
        • Trio O.
        • Saporito F.
        • Oreto G.
        Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention.
        Circ Cardiovasc Interv. 2014; 7: 465-472
        • Gurm H.S.
        • Dixon S.R.
        • Smith D.E.
        • Share D.
        • Lalonde T.
        • Greenbaum A.
        • Moscucci M.
        • BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) Registry
        Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions.
        J Am Coll Cardiol. 2011; 58: 907-914
        • Gupta T.
        • Kolte D.
        • Khera S.
        • Harikrishnan P.
        • Mujib M.
        • Aronow W.S.
        • Jain D.
        • Ahmed A.
        • Cooper H.A.
        • Frishman W.H.
        • Bhatt D.L.
        • Fonarow G.C.
        • Panza J.A.
        Smoker's paradox in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
        J Am Heart Assoc. 2016; 5: 1-11